https://lymphoblastic-hub.com daily 1 2026-04-03T18:57:38.688Z https://lymphoblastic-hub.com/types weekly 0.8 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/lineage weekly 0.7 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/age-related-all weekly 0.7 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/chromosomal-aberrations weekly 0.7 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/disease weekly 0.7 2026-02-12T10:18:00.000Z https://lymphoblastic-hub.com/types/risk weekly 0.7 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/all-related-mutations weekly 0.7 2025-03-06T11:08:00.000Z https://lymphoblastic-hub.com/types/epigenetic-modifier-mutations weekly 0.7 2026-02-04T11:36:00.000Z https://lymphoblastic-hub.com/therapeutics weekly 0.8 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/therapeutics/cellular-therapy weekly 0.7 2025-03-10T09:33:00.000Z https://lymphoblastic-hub.com/therapeutics/chemotherapy weekly 0.7 2025-03-10T09:34:00.000Z https://lymphoblastic-hub.com/therapeutics/tyrosine-kinase-inhibitors weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/therapeutics/car-t-cell-therapy weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/therapeutics/conjugated-antibodies weekly 0.7 2025-03-10T09:34:00.000Z https://lymphoblastic-hub.com/therapeutics/t-cell-engagers weekly 0.7 2025-03-10T09:33:00.000Z https://lymphoblastic-hub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2025-03-10T09:34:00.000Z https://lymphoblastic-hub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2025-03-10T09:35:00.000Z https://lymphoblastic-hub.com/therapeutics/nuclear-receptor-agonists weekly 0.7 2025-03-10T09:34:00.000Z https://lymphoblastic-hub.com/therapeutics/jak-inhibitors weekly 0.7 2025-03-10T09:33:00.000Z https://lymphoblastic-hub.com/therapeutics/antibody-therapy weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/therapeutics/proteasome-inhibitors weekly 0.7 2025-03-10T09:33:00.000Z https://lymphoblastic-hub.com/therapeutics/cell-cycle-inhibitors weekly 0.7 2025-03-10T09:32:00.000Z https://lymphoblastic-hub.com/therapeutics/histone-deacetylase-inhibitor weekly 0.7 2025-03-10T09:32:00.000Z https://lymphoblastic-hub.com/therapeutics/pegasparaginase weekly 0.7 2025-04-10T14:35:00.000Z https://lymphoblastic-hub.com/therapeutics/curcumin weekly 0.7 2025-03-13T20:30:00.000Z https://lymphoblastic-hub.com/therapeutics/gc007g weekly 0.7 2025-03-10T09:32:00.000Z https://lymphoblastic-hub.com/congresses weekly 0.8 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/ash weekly 0.7 2026-01-12T16:24:00.000Z https://lymphoblastic-hub.com/congresses/asco-2022 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/ebmt weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/soho weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/esh weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/costem weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/iach weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/other-events weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/car-t-meetings weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/congresses/eha weekly 0.7 2025-07-03T09:53:00.000Z https://lymphoblastic-hub.com/trials weekly 0.8 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/nct00558519 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ino-vate weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/zuma-3 weekly 0.7 2025-06-03T08:47:00.000Z https://lymphoblastic-hub.com/trials/ecog-acrin-e1910 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall1731 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/alliance-a041703 weekly 0.7 2025-11-20T15:10:00.000Z https://lymphoblastic-hub.com/trials/gimema-lal2317 weekly 0.7 2026-03-31T18:27:00.000Z https://lymphoblastic-hub.com/trials/mt103-211 weekly 0.7 2026-03-31T18:27:00.000Z https://lymphoblastic-hub.com/trials/gmall-bliven weekly 0.7 2026-03-20T14:22:00.000Z https://lymphoblastic-hub.com/trials/felix weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/cart19-be-02 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/sublime weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/interfant-06 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aieop-bfm-all-2009 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/campus-all weekly 0.7 2025-06-03T08:50:00.000Z https://lymphoblastic-hub.com/trials/nopho-2008 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall1131 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/pethema-lal19 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/syrus weekly 0.7 2025-06-03T08:49:00.000Z https://lymphoblastic-hub.com/trials/gimema-all2820 weekly 0.7 2025-06-03T08:51:00.000Z https://lymphoblastic-hub.com/trials/graall-2014 weekly 0.7 2025-11-06T17:06:00.000Z https://lymphoblastic-hub.com/trials/aall0932 weekly 0.7 2025-12-03T16:47:00.000Z https://lymphoblastic-hub.com/trials/graall weekly 0.7 2025-12-03T16:48:00.000Z https://lymphoblastic-hub.com/trials/dfci-all-16-001 weekly 0.7 2025-12-03T16:48:00.000Z https://lymphoblastic-hub.com/trials/polaris-1 weekly 0.7 2025-12-03T16:48:00.000Z https://lymphoblastic-hub.com/trials/ewall-ph03 weekly 0.7 2025-12-03T16:48:00.000Z https://lymphoblastic-hub.com/trials/gmall0703 weekly 0.7 2025-12-03T16:49:00.000Z https://lymphoblastic-hub.com/trials/gmall-evolve weekly 0.7 2025-12-03T16:49:00.000Z https://lymphoblastic-hub.com/trials/graall-2005 weekly 0.7 2025-11-06T17:06:00.000Z https://lymphoblastic-hub.com/trials/precision-t weekly 0.7 2025-04-28T15:33:00.000Z https://lymphoblastic-hub.com/trials/nopho-all2008 weekly 0.7 2025-10-07T15:35:00.000Z https://lymphoblastic-hub.com/trials/jalsg-trial weekly 0.7 2025-09-25T21:05:00.000Z https://lymphoblastic-hub.com/trials/forum weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gimema-lal1913 weekly 0.7 2025-08-21T08:41:00.000Z https://lymphoblastic-hub.com/trials/dfci-all-consortium-trial weekly 0.7 2025-09-12T14:57:00.000Z https://lymphoblastic-hub.com/trials/dcfi-11-001 weekly 0.7 2025-09-12T14:58:00.000Z https://lymphoblastic-hub.com/trials/spark-all weekly 0.7 2025-09-12T14:58:00.000Z https://lymphoblastic-hub.com/trials/aall1931 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/phallcon weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/b1931030 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/b1931010 weekly 0.7 2025-08-14T20:33:00.000Z https://lymphoblastic-hub.com/trials/itcc-059 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/augment-101 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/inocd22 weekly 0.7 2025-05-08T12:47:00.000Z https://lymphoblastic-hub.com/trials/allmrd2014 weekly 0.7 2025-03-27T15:10:00.000Z https://lymphoblastic-hub.com/trials/allmrd2008 weekly 0.7 2025-03-27T15:12:00.000Z https://lymphoblastic-hub.com/trials/therapeutic-advances-in-childhood-leukemia-and-lymphoma-consortium-trial weekly 0.7 2025-03-20T18:01:00.000Z https://lymphoblastic-hub.com/trials/gmall-ph-01 weekly 0.7 2025-03-18T09:22:00.000Z https://lymphoblastic-hub.com/trials/jalsg-t-all213-o weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/jalsg-t-all202-o weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/all-rez-bfm-2002 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/alloha weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/neuf weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall1331 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/alliance-a041501 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/dfci-16-001 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gmall-trial-082013 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/cog-aall0331 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ewall-ino weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/initial-1 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/jplsg-all-r08 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/delphinus weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ponalfil weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/zuma-4 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/hovon-146 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/athena weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/altogether-1 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ukall14 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/nilg-all-1007 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/pethema-all-hr2011 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/graaph-2014 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/jalsg-ph-all202 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ph-all208 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ph-all213 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall0434-1 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/blast weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gimema weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/eliana weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ensign weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall0232 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/golden-gate-study weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aieop-bfm-all-2000 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/tower weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/jzp458-201 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/graaph-2005 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gimema-lal1811 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/ccg-1952 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/aall0434 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gmall2005 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/gmall2014b weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/incb84344-201 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/d-alba weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/nor-graspall-2016 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/rialto weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/mrc-ukallxiiecog-e2993 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/amelia weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/epicovideha weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/sjcrh-total-therapy-16 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/balli-01 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/pall weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/calm weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/study-1010 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/nilg-all-0900 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/interfant-99 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/alcantara weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/trials/bmt-ctn-1101 weekly 0.7 2025-03-10T09:36:00.000Z https://lymphoblastic-hub.com/expert-opinions weekly 0.8 2025-03-10T13:28:00.000Z https://lymphoblastic-hub.com/drug-updates weekly 0.8 2025-03-10T13:28:00.000Z https://lymphoblastic-hub.com/educational-resources weekly 0.8 2026-02-02T17:41:00.000Z https://lymphoblastic-hub.com/educational-resources/articles weekly 0.7 2026-01-12T16:14:00.000Z https://lymphoblastic-hub.com/educational-resources/masterclass weekly 0.7 2026-03-11T11:01:00.000Z https://lymphoblastic-hub.com/educational-resources/spotlights weekly 0.7 2026-01-16T19:38:00.000Z https://lymphoblastic-hub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-12-03T16:01:00.000Z https://lymphoblastic-hub.com/educational-resources/visual-abstracts weekly 0.7 2025-12-03T16:01:00.000Z https://lymphoblastic-hub.com/educational-resources/drug-approvals-in-all weekly 0.7 2026-02-02T14:02:00.000Z https://lymphoblastic-hub.com/medical-information/allo-hsct-outcomes-in-aya-patients-with-acute-leukemia monthly 0.9 2026-04-02T08:35:00.000Z https://lymphoblastic-hub.com/medical-information/pharmacist-intervention-during-calgb-10403-maintenance-in-aya-all monthly 0.9 2026-04-01T10:00:00.000Z https://lymphoblastic-hub.com/medical-information/reduced-chemotherapy-and-chemotherapy-free-regimens-for-patients-with-all monthly 0.9 2026-04-01T10:39:00.000Z https://lymphoblastic-hub.com/medical-information/outcomes-of-cd19-directed-car-t-cell-therapy-in-rr-extramedullary-ball monthly 0.9 2026-03-27T10:00:00.000Z https://lymphoblastic-hub.com/medical-information/pediatric-inspired-regimens-and-hsct-for-aya-patients-with-all monthly 0.9 2026-03-25T10:00:00.000Z https://lymphoblastic-hub.com/medical-information/gmall-bliven-trial-venetoclax-blinatumomab-in-rr-or-mrd-ph-b-all monthly 0.9 2026-03-20T15:42:00.000Z https://lymphoblastic-hub.com/medical-information/where-does-obe-cel-currently-fit-in-the-treatment-algorithm-for-b-cell-all-and-how-might-this-evolve monthly 0.9 2026-03-18T10:37:00.000Z https://lymphoblastic-hub.com/medical-information/bridging-the-gap-implementing-pediatric-inspired-asparaginase-based-regimens-in-aya-patients-with-all monthly 0.9 2026-03-11T10:57:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-recommendations-for-addressing-challenges-in-implementing-asparaginase-based-regimens-in-aya-patients-with-all monthly 0.9 2026-04-01T18:17:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2026-guideline-recommendations-for-aya-patients-with-rr-all monthly 0.9 2026-03-09T08:40:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-main-barriers-associated-with-implementing-asparaginase-based-regimens-in-aya-patients-with-all monthly 0.9 2026-03-30T19:50:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2026-guidelines-first-line-management-of-aya-patients-with-all monthly 0.9 2026-03-06T09:39:00.000Z https://lymphoblastic-hub.com/medical-information/aall1731-trial-blinatumomab-chemotherapy-in-pediatric-patients-with-sr-b-all monthly 0.9 2026-03-04T14:08:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-the-rationale-for-the-use-of-pediatric-inspired-asparaginase-based-regimens-in-aya-patients-with-all monthly 0.9 2026-03-27T14:01:00.000Z https://lymphoblastic-hub.com/medical-information/clinical-outcomes-and-relapse-predictors-after-allo-hsct-in-pediatric-t-allt-lbl monthly 0.9 2026-03-02T09:05:00.000Z https://lymphoblastic-hub.com/medical-information/cart19-be-02-phase-ii-trial-varnimcabtagene-autoleucel-for-rr-b-all monthly 0.9 2026-02-25T16:58:00.000Z https://lymphoblastic-hub.com/medical-information/all09-sublime-blinatumomab-vs-chemotherapy-consolidation-in-de-novo-nd-aya-b-all monthly 0.9 2026-02-18T10:06:00.000Z https://lymphoblastic-hub.com/medical-information/prognostic-significance-of-tp53-mutations-and-vaf-in-nd-all monthly 0.9 2026-02-16T11:00:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-interfant06-chemotherapy-for-infant-kmt2ar-ball monthly 0.9 2026-02-13T16:33:00.000Z https://lymphoblastic-hub.com/medical-information/aieop-bfm-all-2009-phase-iii-trial-results-reducing-daunorubicin-in-children-with-b-all monthly 0.9 2026-02-12T10:34:00.000Z https://lymphoblastic-hub.com/medical-information/pd-1pd-l1-inhibitor-in-combination-with-chemotherapy-or-car-t-cells-for-rr-all monthly 0.9 2026-02-06T09:00:00.000Z https://lymphoblastic-hub.com/medical-information/campus-all-study-real-life-management-of-older-adults-with-ph-all monthly 0.9 2026-02-04T15:36:00.000Z https://lymphoblastic-hub.com/medical-information/felix-phase-ibii-tumor-burden-guided-obe-cel-in-rr-b-all monthly 0.9 2026-02-27T13:22:00.000Z https://lymphoblastic-hub.com/medical-information/venetoclax-inotuzumab-ozogamicin-in-rr-all-phase-i-results monthly 0.9 2026-01-28T09:31:00.000Z https://lymphoblastic-hub.com/medical-information/prevalence-of-early-toxicities-in-pediatric-all-with-the-nopho-all2008-vs-alltogether-protocol monthly 0.9 2026-01-21T09:44:00.000Z https://lymphoblastic-hub.com/medical-information/rapcabtagene-autoleucel-for-rr-b-all-phase-i-multicenter-study monthly 0.9 2026-02-03T11:08:00.000Z https://lymphoblastic-hub.com/medical-information/pcr-vs-ngs-mrd-discordance-in-ph-positive-all-a-retrospective-analysis monthly 0.9 2026-01-16T15:54:00.000Z https://lymphoblastic-hub.com/medical-information/subcutaneous-blinatumomab-in-rr-b-all-phase-iii-extended-follow-up monthly 0.9 2026-01-09T08:47:00.000Z https://lymphoblastic-hub.com/medical-information/a-sandwich-strategy-of-sequential-car-t-cell-therapy-auto-hsct-for-ph-negative-b-all-phase-ii-findings monthly 0.9 2026-01-16T15:54:00.000Z https://lymphoblastic-hub.com/medical-information/strategies-to-prevent-relapse-post-hsct-cellular-therapy-in-b-all monthly 0.9 2026-01-21T14:23:00.000Z https://lymphoblastic-hub.com/medical-information/improved-transplant-outcomes-in-all-with-ptcy-in-the-era-of-novel-therapies monthly 0.9 2025-12-22T09:00:00.000Z https://lymphoblastic-hub.com/medical-information/ruxolitinib-hyper-cvad-chemotherapy-in-rr-ph-like-all-phase-iii-data monthly 0.9 2026-02-20T16:11:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-key-clinical-considerations-for-asparaginase-based-regimens-in-pediatric-vs-aya-patients-with-all monthly 0.9 2026-03-18T15:46:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2025-live-congress-coverage-from-the-all-hub monthly 0.9 2026-02-20T16:12:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-acute-lymphoblastic-leukemia monthly 0.9 2026-02-20T12:58:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-in-rr-b-all-post-cd19-car-t-cell-therapy-a-retrospective-analysis monthly 0.9 2026-01-16T15:55:00.000Z https://lymphoblastic-hub.com/medical-information/how-can-therapeutic-drug-monitoring-and-premedication-be-applied-in-clinical-practice-to-optimize-pegaspargase-treatment-in-patients-with-all monthly 0.9 2026-01-19T14:12:00.000Z https://lymphoblastic-hub.com/medical-information/alliance-a041703-cohort-1-inotuzumab-ozogamicin-followed-by-blinatumomab-in-older-patients-with-nd-b-all monthly 0.9 2026-01-16T15:56:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-asparaginase-discontinuation-on-outcomes-in-nd-all-a-chinese-retrospective-study monthly 0.9 2026-01-16T15:56:00.000Z https://lymphoblastic-hub.com/medical-information/tisa-cel-in-rr-b-all-real-world-data-from-cibmtr monthly 0.9 2026-01-16T15:57:00.000Z https://lymphoblastic-hub.com/medical-information/felix-trial-obe-cel-for-rr-b-all monthly 0.9 2026-02-20T16:13:00.000Z https://lymphoblastic-hub.com/medical-information/phase-i-study-of-meta-10-19-in-rr-b-cell-all monthly 0.9 2026-01-16T15:57:00.000Z https://lymphoblastic-hub.com/medical-information/fda-grants-fast-track-designation-for-4a10-in-all monthly 0.9 2026-02-20T15:45:00.000Z https://lymphoblastic-hub.com/medical-information/graall-2014-trial-age-adapted-chemotherapy-and-mrd-oriented-transplant-for-ph-negative-all monthly 0.9 2026-01-16T15:58:00.000Z https://lymphoblastic-hub.com/medical-information/asparaginase-optimization-in-aya-patients-with-all-us-consensus-panel-recommendations monthly 0.9 2025-11-07T09:14:00.000Z https://lymphoblastic-hub.com/medical-information/flumatinib-efficacy-and-safety-in-de-novo-ph-all monthly 0.9 2025-10-31T12:32:00.000Z https://lymphoblastic-hub.com/medical-information/ehaeln-guidance-on-blast-reporting-in-acute-leukemias monthly 0.9 2025-10-31T09:34:00.000Z https://lymphoblastic-hub.com/medical-information/dasatinib-real-world-safety-profiles-in-pediatric-patients monthly 0.9 2025-10-27T09:29:00.000Z https://lymphoblastic-hub.com/medical-information/allogeneic-hsct-in-cr2-for-ayas-with-all-a-dual-center-study monthly 0.9 2026-02-20T16:13:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-in-relapsedrefractory-ph-all-real-world-outcomes monthly 0.9 2026-02-20T15:49:00.000Z https://lymphoblastic-hub.com/medical-information/a-phase-iii-trial-wu-cart-007-for-relapsedrefractory-t-all-or-lbl monthly 0.9 2025-10-17T08:09:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-tki-for-de-novo-or-relapsed-ph-b-all monthly 0.9 2026-02-20T16:16:00.000Z https://lymphoblastic-hub.com/medical-information/pediatric-based-protocol-improves-outcomes-in-elderly-patients-with-all monthly 0.9 2025-10-13T07:54:00.000Z https://lymphoblastic-hub.com/medical-information/iach-2025-live-congress-coverage-from-the-all-hub monthly 0.9 2026-02-20T16:15:00.000Z https://lymphoblastic-hub.com/medical-information/biologics-license-application-for-orca-t-for-hematological-malignancies-granted-priority-review-by-fda monthly 0.9 2025-11-06T14:56:00.000Z https://lymphoblastic-hub.com/medical-information/pk-model-predicts-peg-asparaginase-inactivation-in-all monthly 0.9 2025-10-08T13:55:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-for-patients-with-cd19-acute-leukemias-and-preexisting-comorbidities monthly 0.9 2026-02-20T16:16:00.000Z https://lymphoblastic-hub.com/medical-information/brexu-cel-in-rr-b-all-with-cns-involvement-real-world-outcomes monthly 0.9 2026-02-20T16:17:00.000Z https://lymphoblastic-hub.com/medical-information/jalsg-trial-dasatinib-vs-imatinib-in-adult-ph-all monthly 0.9 2025-09-26T10:23:00.000Z https://lymphoblastic-hub.com/medical-information/the-calgb-10403-regimen-in-aya-patients-with-all-a-real-world-retrospective-cohort-study monthly 0.9 2025-09-19T11:35:00.000Z https://lymphoblastic-hub.com/medical-information/phase-iii-forum-trial-mrd-status-predicts-transplant-outcomes-in-pediatric-all monthly 0.9 2025-09-16T08:23:00.000Z https://lymphoblastic-hub.com/medical-information/pediatric-inspired-pegylated-asparaginase-based-regimens-in-adults-with-all monthly 0.9 2026-01-16T10:29:00.000Z https://lymphoblastic-hub.com/medical-information/campus-all-subgroup-analysis-polyethylene-glycolated-pegaspargase-in-older-patients-with-ph-negative-all monthly 0.9 2025-09-11T12:10:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-asparaginase-discontinuation-on-outcomes-in-all monthly 0.9 2025-09-10T09:26:00.000Z https://lymphoblastic-hub.com/medical-information/effects-of-a-pediatric-inspired-chemotherapy-regimen-vs-an-adult-regimen-on-cns-relapse-risk-in-adult-patients-with-all monthly 0.9 2025-09-08T12:16:00.000Z https://lymphoblastic-hub.com/medical-information/soho-2025-live-congress-feed monthly 0.9 2025-09-10T11:29:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-tp53-mutations-on-outcomes-following-blinatumomab-treatment-in-adults-with-b-cell-all monthly 0.9 2025-08-29T09:24:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-for-patients-with-mrd-positive-ph-negative-b-all-a-pediatric-inspired-chemotherapy-regimen-based-on-the-gimema-lal1913-protocol monthly 0.9 2025-08-22T08:35:00.000Z https://lymphoblastic-hub.com/medical-information/dose-optimization-of-inotuzumab-ozogamicin-for-adult-b-all monthly 0.9 2025-08-15T09:04:00.000Z https://lymphoblastic-hub.com/medical-information/subcutaneous-blinatumomab-in-relapsedrefractory-b-all-results-from-phase-iii-dose-expansion-study monthly 0.9 2025-08-13T08:58:00.000Z https://lymphoblastic-hub.com/medical-information/dose-dependent-outcomes-with-inotuzumab-ozogamicin-in-b-all monthly 0.9 2025-08-04T16:26:00.000Z https://lymphoblastic-hub.com/medical-information/tafasitamab-plus-da-epoch-r-in-newly-diagnosed-ph-b-all monthly 0.9 2025-07-29T15:26:00.000Z https://lymphoblastic-hub.com/medical-information/obecabtagene-autoleucel-granted-marketing-authorization-by-the-european-commission-for-the-treatment-of-rr-b-all monthly 0.9 2026-02-20T16:18:00.000Z https://lymphoblastic-hub.com/medical-information/syrus-phase-iii-trial-safety-and-efficacy-of-surovatamig-azd0486-in-patients-with-rr-b-all monthly 0.9 2025-07-17T17:42:00.000Z https://lymphoblastic-hub.com/medical-information/zuma-3-trial-5-year-follow-up-analysis-of-brexu-cel-in-adults-with-rr-b-all monthly 0.9 2025-07-17T08:43:00.000Z https://lymphoblastic-hub.com/medical-information/ecog-acrin-e1910-subgroup-analysis-blinatumomab-chemotherapy-consolidation-in-younger-adults-with-mrd-negative-bcrabl1-negative-b-all monthly 0.9 2025-07-09T14:54:00.000Z https://lymphoblastic-hub.com/medical-information/calgb-10403-long-term-follow-up-outcomes-with-intensive-chemotherapy-for-aya-with-all monthly 0.9 2025-07-01T08:25:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2025-congress-coverage-treatment-for-newly-diagnosed-and-rr-all-part-4 monthly 0.9 2025-06-25T09:45:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2025-congress-coverage-treatment-for-newly-diagnosed-and-rr-all-part-3 monthly 0.9 2025-06-25T09:43:00.000Z https://lymphoblastic-hub.com/medical-information/all-hub-spotlight-ecog-acrin-e1910-a-phase-iii-trial-of-blinatumomab-plus-chemotherapy-vs-chemotherapy-alone-in-patients-with-newly-diagnosed-bcrabl1-negative-b-all monthly 0.9 2025-07-01T11:05:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2025-congress-coverage-treatment-for-newly-diagnosed-and-rr-all-part-2 monthly 0.9 2025-06-25T09:45:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2025-congress-coverage-treatment-for-newly-diagnosed-and-rr-all-part-1 monthly 0.9 2025-06-25T09:46:00.000Z https://lymphoblastic-hub.com/medical-information/2025-asco25-annual-meetinglive-congress-coverage-from-the-all-hub monthly 0.9 2026-02-23T08:57:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2025-abstracts-whats-hot-in-all monthly 0.9 2026-02-20T16:19:00.000Z https://lymphoblastic-hub.com/medical-information/safety-and-efficacy-of-brexu-cel-in-rr-cns-b-cell-all-a-real-world-study monthly 0.9 2025-06-06T11:10:00.000Z https://lymphoblastic-hub.com/medical-information/phallcon-impact-of-mrd-negativity-post-induction-with-ponatinib-vs-imatinib-in-newly-diagnosed-ph-all monthly 0.9 2025-06-05T07:10:00.000Z https://lymphoblastic-hub.com/medical-information/auto-hsct-in-ph-all-a-retrospective-analysis-by-the-acute-leukemia-working-party-of-the-ebmt monthly 0.9 2025-05-29T14:26:00.000Z https://lymphoblastic-hub.com/medical-information/dasatinib-plus-sequential-cd19cd22-car-t-cell-therapy-in-adult-patients-with-newly-diagnosed-ph-all monthly 0.9 2025-05-23T13:26:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-andor-inotuzumab-as-pre-hsct-salvage-therapy-in-adult-patients-with-rr-all-and-mpal monthly 0.9 2025-05-20T13:48:00.000Z https://lymphoblastic-hub.com/medical-information/efficacy-and-safety-of-cart22-65s-in-children-and-adults-with-relapsed-b-all-parallel-phase-i-studies monthly 0.9 2025-05-15T09:35:00.000Z https://lymphoblastic-hub.com/medical-information/phallcon-an-exploratory-post-hoc-analysis-of-the-impact-of-ponatinib-vs-imatinib-on-pros-in-ph-all monthly 0.9 2025-05-13T14:12:00.000Z https://lymphoblastic-hub.com/medical-information/real-world-effectiveness-and-safety-of-inotuzumab-ozogamicin-in-adult-patients-with-rr-b-all monthly 0.9 2025-05-08T14:15:00.000Z https://lymphoblastic-hub.com/medical-information/lyophilized-pegaspargase-for-japanese-patients-with-b-all-results-from-a-phase-ii-trial monthly 0.9 2025-05-01T13:52:00.000Z https://lymphoblastic-hub.com/medical-information/precision-t-a-phase-iii-trial-of-orca-t-vs-soc-for-cgvhd-prophylaxis-in-advanced-hematologic-malignancies monthly 0.9 2025-04-29T15:44:00.000Z https://lymphoblastic-hub.com/medical-information/uk-mhra-grants-conditional-marketing-authorization-to-obecabtagene-autoleucel-for-the-treatment-of-adult-patients-with-rr-b-all monthly 0.9 2025-04-29T14:01:00.000Z https://lymphoblastic-hub.com/medical-information/zuma-3-trial-3-year-follow-up-analysis monthly 0.9 2025-04-24T13:42:00.000Z https://lymphoblastic-hub.com/medical-information/talicabtagene-autoleucel-for-patients-with-rr-b-cell-malignancies-results-from-a-phase-iii-trial monthly 0.9 2025-04-23T17:09:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-addition-of-rituximab-to-standard-treatment-in-patients-with-nd-ph-b-all-a-retrospective-analysis monthly 0.9 2025-04-17T17:27:00.000Z https://lymphoblastic-hub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-antibody-and-car-therapies monthly 0.9 2026-02-20T15:57:00.000Z https://lymphoblastic-hub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-transplant-and-outcomes monthly 0.9 2025-04-15T09:31:00.000Z https://lymphoblastic-hub.com/medical-information/venetoclax-plus-chemotherapy-in-pediatric-and-aya-patients-with-rr-all-phase-i-trial-results monthly 0.9 2025-04-11T09:56:00.000Z https://lymphoblastic-hub.com/medical-information/addition-of-ino-to-hyper-cvad-and-blinatumomab-in-younger-adults-with-newly-diagnosed-ph-negative-b-all monthly 0.9 2026-02-20T16:20:00.000Z https://lymphoblastic-hub.com/medical-information/allmrd2014-trial-continuous-dasatinib-and-reduced-intensity-chemotherapy-in-patients-with-ph-all monthly 0.9 2025-03-27T15:46:00.000Z https://lymphoblastic-hub.com/medical-information/all-hematotox-score-predicting-post-car-t-cell-therapy-hematotoxicity-in-b-cell-all monthly 0.9 2025-03-24T17:26:00.000Z https://lymphoblastic-hub.com/medical-information/vincristine-sulfate-liposome-injection-with-combination-chemotherapy-in-children-and-young-adults-with-relapsed-all monthly 0.9 2025-03-20T19:08:00.000Z https://lymphoblastic-hub.com/medical-information/gmall-ph-01-phase-ii-trial-final-analysis-dasatinib-plus-standard-chemotherapy-for-adult-patients-with-ph-all monthly 0.9 2025-03-18T19:08:00.000Z https://lymphoblastic-hub.com/medical-information/oral-curcumin-for-the-prevention-of-vincristine-induced-neuropathy-in-pediatric-all-phase-iii-trial-results monthly 0.9 2025-03-14T10:51:00.000Z https://lymphoblastic-hub.com/medical-information/inaticabtagene-autoleucel-for-adult-patients-with-rr-b-all-phase-ii-trial-results monthly 0.9 2025-03-11T14:57:00.000Z https://lymphoblastic-hub.com/medical-information/jalsg-t-all213-o-nelarabine-combined-chemotherapy-in-newly-diagnosed-t-all monthly 0.9 2026-02-20T15:57:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-treatment-protocol-deviations-on-outcomes-in-the-all-rez-bfm-2002-study monthly 0.9 2025-03-04T10:45:00.000Z https://lymphoblastic-hub.com/medical-information/optimal-use-of-mrd-in-adult-patients-with-all-recommendations-from-us-experts monthly 0.9 2025-02-27T18:30:00.000Z https://lymphoblastic-hub.com/medical-information/optimizing-bridging-therapies-to-car-t-for-children-and-young-adults-with-rr-all monthly 0.9 2025-02-25T20:16:00.000Z https://lymphoblastic-hub.com/medical-information/2025-tandem-meetings-or-transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr-congress-coverage monthly 0.9 2025-02-21T15:46:00.000Z https://lymphoblastic-hub.com/medical-information/7th-european-car-t-cell-meeting-congress-coverage-catchup monthly 0.9 2025-02-19T11:17:00.000Z https://lymphoblastic-hub.com/medical-information/visual-abstract-or-real-world-use-of-blinatumomab-in-adult-all monthly 0.9 2025-09-19T12:06:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-tp53-mutations-on-treatment-failure-patterns-in-patients-treated-with-blinatumomab monthly 0.9 2025-02-13T16:02:00.000Z https://lymphoblastic-hub.com/medical-information/felix-trial-mrd-negative-remission-and-clinical-outcomes-in-rr-b-all-treated-with-obe-cel monthly 0.9 2026-02-20T15:59:00.000Z https://lymphoblastic-hub.com/medical-information/phase-iv-b1931030-study-inotuzumab-ozogamicin-dose-optimization-in-adults-with-rr-b-all monthly 0.9 2026-02-20T16:00:00.000Z https://lymphoblastic-hub.com/medical-information/consolidation-therapy-in-newly-diagnosed-adult-patients-with-ph-negative-b-cell-all monthly 0.9 2026-02-23T08:55:00.000Z https://lymphoblastic-hub.com/medical-information/ec-approves-blinatumomab-as-consolidation-for-adult-patients-with-newly-diagnosed-ph-cd19-b-all monthly 0.9 2025-01-30T17:04:00.000Z https://lymphoblastic-hub.com/medical-information/optimizing-treatment-for-adults-with-rr-ph-negative-b-cell-all monthly 0.9 2025-09-26T12:30:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-early-ngs-mrd-negativity-on-outcomes-in-b-cell-all-a-retrospective-analysis monthly 0.9 2025-01-30T10:02:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-delaying-pegaspargase-during-induction-on-hepatotoxicity-in-adult-patients-with-all monthly 0.9 2025-01-21T17:52:00.000Z https://lymphoblastic-hub.com/medical-information/overview-of-blinatumomab-for-pediatric-b-all monthly 0.9 2025-02-14T11:35:00.000Z https://lymphoblastic-hub.com/medical-information/aieop-bfm-all-2009-long-term-results-reduced-dose-daunorubicin-for-pediatric-patients-with-b-cell-all monthly 0.9 2025-01-16T20:43:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-ponatinib-in-patients-with-newly-diagnosed-ph-all-phase-ii-findings monthly 0.9 2025-01-09T18:20:00.000Z https://lymphoblastic-hub.com/medical-information/ash24-treatment-for-relapsedrefractory-all monthly 0.9 2024-12-19T10:40:00.000Z https://lymphoblastic-hub.com/medical-information/ash24-first-line-and-emerging-therapies-for-all monthly 0.9 2024-12-19T10:40:00.000Z https://lymphoblastic-hub.com/medical-information/improved-disease-free-survival-with-blinatumomab-plus-chemotherapy-in-pediatric-higher-risk-b-all-aall1731-study monthly 0.9 2024-12-18T06:39:00.000Z https://lymphoblastic-hub.com/medical-information/obecabtagene-autoleucel-in-adult-patients-with-rr-b-all-results-from-felix-trial monthly 0.9 2024-12-13T07:04:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-as-last-consolidation-prior-to-allo-hsct-in-pediatric-and-young-adult-patients-with-b-cell-all monthly 0.9 2024-12-02T08:11:00.000Z https://lymphoblastic-hub.com/medical-information/jzp458-in-alllbl-complete-follow-up-results-from-aall1931-trial monthly 0.9 2024-12-02T08:06:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2024-top-abstracts-in-all monthly 0.9 2024-12-02T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/hypersensitivity-reactions-to-asparaginase-incidence-identification-management-and-overcoming-challenges monthly 0.9 2026-02-02T17:37:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-clinical-considerations-for-prescribing-recombinant-erwinia-asparaginase-in-pediatric-and-young-adult-patients-with-all monthly 0.9 2024-11-27T16:22:00.000Z https://lymphoblastic-hub.com/medical-information/u-s-fda-grants-fast-track-designation-to-cell-cycle-inhibitor-lbs-007 monthly 0.9 2024-11-27T16:16:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-maintaining-mrd-negativity-post-induction-on-survival-outcomes-in-patients-with-b-all monthly 0.9 2024-11-26T15:41:00.000Z https://lymphoblastic-hub.com/medical-information/high-dna-input-and-next-generation-sequencing-peripheral-blood-mrd-detection-in-patients-with-bcp-all monthly 0.9 2024-11-21T13:14:00.000Z https://lymphoblastic-hub.com/medical-information/revumenib-receives-fda-approval-for-adult-and-pediatric-patients-aged-1-year-with-rr-all-and-a-kmt2a-translocation monthly 0.9 2024-11-25T10:12:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-plus-low-intensity-chemotherapy-in-older-patients-with-newly-diagnosed-cd22-ph-b-all-results-from-the-ewall-ino-trial monthly 0.9 2024-11-18T10:00:00.000Z https://lymphoblastic-hub.com/medical-information/long-term-survival-outcomes-in-patients-with-all-who-were-alive-and-disease-free-2-years-after-allo-hsct monthly 0.9 2024-11-18T08:13:00.000Z https://lymphoblastic-hub.com/medical-information/fda-grants-marketing-approval-for-obecabtagene-autoleucel-for-adult-patients-with-rr-b-all monthly 0.9 2024-11-11T17:12:00.000Z https://lymphoblastic-hub.com/medical-information/anti-cd19-car-t-cell-therapy-with-shrna-il-6-gene-silencing-element-for-patients-with-rr-b-all monthly 0.9 2024-11-07T12:14:00.000Z https://lymphoblastic-hub.com/medical-information/addition-of-venetoclax-to-hyper-cvad-nelarabine-pegasp-for-t-alllbl-2-year-follow-up-from-the-phase-ii-trial monthly 0.9 2024-11-05T11:54:00.000Z https://lymphoblastic-hub.com/medical-information/comparison-of-outcomes-of-patients-aged-26-years-with-rr-b-all-in-zuma-3-and-historical-trials monthly 0.9 2024-10-30T09:21:00.000Z https://lymphoblastic-hub.com/medical-information/role-of-allo-hsct-in-patients-with-ph-like-all-in-first-complete-remission monthly 0.9 2024-10-25T08:47:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-in-combination-with-dexamethasone-as-induction-for-older-patients-with-b-all-results-from-the-initial-1-study monthly 0.9 2024-10-21T13:56:00.000Z https://lymphoblastic-hub.com/medical-information/the-2023-jsh-practical-guidelines-for-hematological-malignancies-all monthly 0.9 2024-10-21T12:10:00.000Z https://lymphoblastic-hub.com/medical-information/post-hoc-analysis-of-prior-allo-hsct-conditioning-regimens-used-following-blinatumomab-or-chemotherapy-in-childhood-b-all monthly 0.9 2024-10-17T15:13:00.000Z https://lymphoblastic-hub.com/medical-information/factors-influencing-survival-following-first-relapse-in-all-a-children-s-oncology-group-study monthly 0.9 2024-10-17T15:13:00.000Z https://lymphoblastic-hub.com/medical-information/correlation-between-igf-i-and-chemotherapy-related-toxicities-in-childhood-all monthly 0.9 2024-10-09T09:07:00.000Z https://lymphoblastic-hub.com/medical-information/how-to-optimize-dosing-regimens-for-recombinant-asparaginase-in-all monthly 0.9 2025-01-14T12:34:00.000Z https://lymphoblastic-hub.com/medical-information/outcomes-in-patients-with-first-relapsed-childhood-all-in-japan-results-from-the-jplsg-all-r08-study monthly 0.9 2024-10-03T15:11:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-induction-regimen-and-allo-hsct-on-survival-outcomes-in-patients-with-ph-all monthly 0.9 2024-10-03T13:54:00.000Z https://lymphoblastic-hub.com/medical-information/ph-positive-all-an-overview-of-the-genomic-landscape-epidemiology-diagnosis-and-treatment-strategies monthly 0.9 2024-10-02T13:59:00.000Z https://lymphoblastic-hub.com/medical-information/reduced-dose-chemotherapy-plus-blinatumomab-in-patients-with-ph-bcp-all-results-from-a-phase-ii-trial monthly 0.9 2024-10-03T14:04:00.000Z https://lymphoblastic-hub.com/medical-information/tumor-burden-guided-dosing-of-obe-cel-in-patients-with-rr-b-cell-all-results-from-the-felix-trial monthly 0.9 2024-09-26T16:50:00.000Z https://lymphoblastic-hub.com/medical-information/toxicities-associated-with-tki-maintenance-therapy-following-allo-hsct-in-patients-with-ph-all monthly 0.9 2024-09-23T09:02:00.000Z https://lymphoblastic-hub.com/medical-information/ph-like-all-an-overview-of-the-genomic-landscape-epidemiology-diagnosis-and-treatment monthly 0.9 2026-02-02T17:40:00.000Z https://lymphoblastic-hub.com/medical-information/delphinus-daratumumab-plus-chemotherapy-in-pediatric-patients-with-rr-all-or-lbl monthly 0.9 2024-09-18T09:51:00.000Z https://lymphoblastic-hub.com/medical-information/management-of-complications-of-car-t-cell-therapies-in-europe monthly 0.9 2024-09-11T12:12:00.000Z https://lymphoblastic-hub.com/medical-information/soho-2024-live-congress-feed monthly 0.9 2024-09-16T12:38:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-in-adult-patients-with-mrd-negative-b-all-interim-results-from-the-ecog-acrin-e1910-trial monthly 0.9 2024-09-09T09:08:00.000Z https://lymphoblastic-hub.com/medical-information/bacterial-and-fungal-infection-risk-in-aya-and-pediatric-patients-with-all monthly 0.9 2024-09-03T15:11:00.000Z https://lymphoblastic-hub.com/medical-information/outpatient-administration-of-car-t-cell-therapies-in-patients-with-hematological-malignancies monthly 0.9 2024-09-03T07:59:00.000Z https://lymphoblastic-hub.com/medical-information/topline-results-from-the-real-world-study-of-org-101-for-cd19-b-all monthly 0.9 2024-08-30T14:30:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-the-type-of-tki-prior-to-allo-hsct-on-outcomes-in-patients-with-ph-all monthly 0.9 2024-09-02T14:33:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-leukemic-molecular-profile-on-the-efficacy-of-inotuzumab-ozogamicin-in-rr-all monthly 0.9 2024-09-02T14:31:00.000Z https://lymphoblastic-hub.com/medical-information/vitamin-d-and-a-deficiency-and-infection-related-complications-in-pediatric-patients-with-all-undergoing-intensive-induction-chemotherapy monthly 0.9 2024-09-02T14:29:00.000Z https://lymphoblastic-hub.com/medical-information/outcomes-following-relapse-post-allo-hct-in-patients-with-ph-all monthly 0.9 2024-09-02T14:26:00.000Z https://lymphoblastic-hub.com/medical-information/imatinib-vs-dasatinib-maintenance-therapy-post-transplant-in-patients-with-ph-all monthly 0.9 2024-09-02T14:21:00.000Z https://lymphoblastic-hub.com/medical-information/brexu-cel-for-patients-with-rr-b-all-4-year-follow-up-from-the-zuma-3-trial monthly 0.9 2026-02-20T15:55:00.000Z https://lymphoblastic-hub.com/medical-information/jzp458-in-alllbl-post-hoc-analysis-from-aall1931-trial monthly 0.9 2024-08-01T12:57:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-plus-chemotherapy-and-allo-hsct-in-newly-diagnosed-ph-all-final-results-from-the-ponalfil-trial monthly 0.9 2026-02-23T08:56:00.000Z https://lymphoblastic-hub.com/medical-information/key-considerations-when-preparing-patients-with-all-for-car-t-cell-therapy monthly 0.9 2025-09-26T12:31:00.000Z https://lymphoblastic-hub.com/medical-information/an-asparaginase-based-pediatric-inspired-chemotherapy-regimen-outcomes-for-older-patients-with-ph-all monthly 0.9 2024-07-09T15:13:00.000Z https://lymphoblastic-hub.com/medical-information/the-addition-of-blinatumomab-to-prephase-consolidation-and-after-intensification-in-patients-with-b-all-updated-results-from-the-hovon-146-trial monthly 0.9 2024-07-02T20:23:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-vs-imatinib-in-patients-with-newly-diagnosed-ph-all-results-from-the-phallcon-trial monthly 0.9 2026-02-23T08:56:00.000Z https://lymphoblastic-hub.com/medical-information/eha2024-treatments-for-relapsed-or-refractory-all monthly 0.9 2026-02-20T15:58:00.000Z https://lymphoblastic-hub.com/medical-information/eha2024-frontline-and-emerging-therapies-for-all monthly 0.9 2024-07-31T09:10:00.000Z https://lymphoblastic-hub.com/medical-information/patient-and-transplant-related-prognostic-factors-for-post-transplant-outcomes-in-patients-with-t-all monthly 0.9 2024-06-25T15:26:00.000Z https://lymphoblastic-hub.com/medical-information/safety-and-efficacy-of-allo-hsct-for-patients-with-rr-t-alllbl-who-achieved-cr-after-cd7-directed-car-t-cell-therapy monthly 0.9 2024-06-18T20:04:00.000Z https://lymphoblastic-hub.com/medical-information/u-s-fda-approves-blinatumomab-as-consolidation-for-adult-and-pediatric-patients-with-cd19-b-all-irrespective-of-mrd-status monthly 0.9 2024-06-18T15:06:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2024-abstracts-what-s-hot-in-all monthly 0.9 2024-06-18T11:34:00.000Z https://lymphoblastic-hub.com/medical-information/survival-outcomes-in-patients-with-ph-all-following-failure-with-a-ponatinib-based-regimen monthly 0.9 2024-05-29T12:06:00.000Z https://lymphoblastic-hub.com/medical-information/ewall-prognostic-index-for-the-risk-stratification-of-adult-patients-with-all monthly 0.9 2024-05-22T15:43:00.000Z https://lymphoblastic-hub.com/medical-information/2023-eln-recommendations-part-2-clinical-management-of-adult-all monthly 0.9 2026-01-16T19:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-effect-of-blinatumomab-prior-to-allo-hsct-in-adult-patients-with-b-all monthly 0.9 2024-05-15T08:36:00.000Z https://lymphoblastic-hub.com/medical-information/base-edited-cd7-car-t-cell-therapy-for-childhood-rr-t-all-preliminary-results-from-a-phase-i-trial monthly 0.9 2024-05-08T18:28:00.000Z https://lymphoblastic-hub.com/medical-information/visual-abstract-or-phase-iii-graaph-2014-trial-nilotinib-ara-c-in-adult-patients-with-ph-all monthly 0.9 2024-05-08T18:26:00.000Z https://lymphoblastic-hub.com/medical-information/efficacy-and-safety-of-car-t-cell-reinfusion-in-children-and-young-adults-with-rr-b-all monthly 0.9 2024-05-01T13:56:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-mrd-at-hsct-in-childhood-b-all-results-from-the-forum-trial monthly 0.9 2024-04-30T12:33:00.000Z https://lymphoblastic-hub.com/medical-information/2023-eln-recommendations-part-1-diagnosis-prognosis-and-assessment-of-adult-all monthly 0.9 2026-01-16T19:22:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-disease-burden-and-loss-of-bca-on-outcomes-after-tisa-cel-infusion-in-pediatric-and-young-adults-with-rr-b-all monthly 0.9 2026-02-20T15:58:00.000Z https://lymphoblastic-hub.com/medical-information/the-role-of-allogeneic-transplant-in-adults-with-ph-all-in-complete-molecular-remission monthly 0.9 2024-04-09T11:47:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-the-optimal-use-of-asparaginase-in-adults-with-all monthly 0.9 2024-04-08T14:24:00.000Z https://lymphoblastic-hub.com/medical-information/optimizing-car-t-cell-therapy-for-adult-patients-with-rr-b-all monthly 0.9 2024-04-03T14:39:00.000Z https://lymphoblastic-hub.com/medical-information/priority-review-of-a-new-drug-application-for-revumenib-in-the-treatment-of-patients-with-rr-kmt2ar-aml-and-all monthly 0.9 2024-03-28T15:45:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-for-adult-patients-with-b-all-in-cr-with-positive-mrd-a-phase-ii-study monthly 0.9 2024-03-25T11:18:00.000Z https://lymphoblastic-hub.com/medical-information/how-i-treat-case-studies-on-treatment-approaches-in-children-with-etp-all monthly 0.9 2026-02-02T17:37:00.000Z https://lymphoblastic-hub.com/medical-information/safety-and-efficacy-of-subcutaneous-blinatumomab-in-adult-patients-with-rr-b-all-phase-ib-trial monthly 0.9 2025-02-06T13:15:00.000Z https://lymphoblastic-hub.com/medical-information/u-s-fda-approves-ponatinib-plus-chemotherapy-for-adult-patients-with-newly-diagnosed-ph-all monthly 0.9 2024-03-20T17:16:00.000Z https://lymphoblastic-hub.com/medical-information/acute-lymphoblastic-leukemia-an-overview-of-etiology-epidemiology-pathophysiology-diagnosis-and-treatment monthly 0.9 2026-02-02T17:40:00.000Z https://lymphoblastic-hub.com/medical-information/the-prognostic-impact-of-genetic-alterations-and-mrd-status-in-kmt2a-rearranged-b-all monthly 0.9 2024-03-06T13:21:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-receives-u-s-fda-approval-for-pediatric-patients-aged-1-year-with-cd22-rr-b-all monthly 0.9 2024-03-08T07:40:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-inotuzumab-ozogamicin-prior-to-allo-hsct-in-adult-patients-with-rr-b-all monthly 0.9 2026-02-20T15:59:00.000Z https://lymphoblastic-hub.com/medical-information/safety-of-low-dose-inotuzumab-ozogamicin-posttransplant-in-b-all-phase-i-trial monthly 0.9 2024-03-04T17:19:00.000Z https://lymphoblastic-hub.com/medical-information/debate-should-patients-with-ph-all-who-reach-mrd-negativity-receive-allo-hsct monthly 0.9 2024-02-28T13:11:00.000Z https://lymphoblastic-hub.com/medical-information/pass-all-study-pediatric-inspired-vs-adult-regimens-in-aya-patients-with-high-risk-ph-b-all monthly 0.9 2024-02-27T09:11:00.000Z https://lymphoblastic-hub.com/medical-information/safety-and-efficacy-of-donor-derived-anti-cd19-car-t-cell-therapy-for-rr-b-all-post-allo-hsct monthly 0.9 2026-02-20T16:01:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-obesity-on-asparaginase-dosing-and-outcomes-in-adult-patients-with-all monthly 0.9 2024-02-18T17:49:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-plus-chemotherapy-in-pediatric-b-all-itcc-059-trial monthly 0.9 2024-02-09T11:22:00.000Z https://lymphoblastic-hub.com/medical-information/long-term-outcomes-of-inotuzumab-ozogamicin-plus-allo-hsct-conditioning-regimen-in-cd22-lymphoid-malignancies monthly 0.9 2024-01-31T16:24:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-socioeconomic-factors-on-survival-outcomes-in-adult-all-key-updates-from-ash-2023 monthly 0.9 2024-01-30T16:50:00.000Z https://lymphoblastic-hub.com/medical-information/novel-treatment-strategies-for-adult-patients-with-all-key-updates-from-ash-2023 monthly 0.9 2024-05-08T14:58:00.000Z https://lymphoblastic-hub.com/medical-information/prevention-and-management-of-relapse-after-car-t-cell-therapy-in-b-all monthly 0.9 2024-01-22T13:42:00.000Z https://lymphoblastic-hub.com/medical-information/fda-accepts-a-biologics-license-application-for-obe-cel-in-patients-with-rr-b-all monthly 0.9 2024-11-11T17:11:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2023-optimizing-conditioning-regimens-for-allo-hsct-in-all monthly 0.9 2024-01-22T12:19:00.000Z https://lymphoblastic-hub.com/medical-information/real-world-outcomes-of-brexu-cel-in-rr-adult-all monthly 0.9 2024-01-19T10:45:00.000Z https://lymphoblastic-hub.com/medical-information/is-next-generation-sequencing-a-useful-tool-for-the-risk-stratification-of-patients-with-t-all monthly 0.9 2024-01-18T14:28:00.000Z https://lymphoblastic-hub.com/medical-information/tisagenlecleucel-vs-standard-of-care-in-children-and-young-adults-with-rr-all monthly 0.9 2026-02-20T16:03:00.000Z https://lymphoblastic-hub.com/medical-information/modified-chemotherapy-for-pediatric-patients-with-down-syndrome-and-high-risk-b-all monthly 0.9 2024-01-05T16:03:00.000Z https://lymphoblastic-hub.com/medical-information/efficacy-and-safety-of-sequential-cd19-and-cd22-car-t-cell-therapy-for-childhood-rr-b-all monthly 0.9 2023-12-22T13:29:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-socioeconomic-disparities-in-the-access-to-pediatric-clinical-trials monthly 0.9 2023-12-21T12:44:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-strategies-to-optimize-outcomes-in-pediatricaya-patients-receiving-car-t-cells monthly 0.9 2025-08-05T13:30:00.000Z https://lymphoblastic-hub.com/medical-information/how-do-you-treat-older-patients-with-newly-diagnosed-b-all monthly 0.9 2023-12-13T23:49:00.000Z https://lymphoblastic-hub.com/medical-information/esmo-clinical-practice-guidelines-targeted-therapies-for-adult-acute-lymphoblastic-leukemia monthly 0.9 2026-02-17T11:24:00.000Z https://lymphoblastic-hub.com/medical-information/progress-and-challenges-of-car-t-cell-therapies-for-t-cell-leukemia-and-lymphoma monthly 0.9 2023-11-28T14:07:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2023-abstracts-what-s-hot-in-all monthly 0.9 2023-12-05T14:42:00.000Z https://lymphoblastic-hub.com/medical-information/nelarabine-for-the-treatment-of-t-cell-acute-lymphoblastic-leukemialymphoma monthly 0.9 2023-11-27T17:29:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-new-in-car-t-cell-therapy-for-pediatric-acute-lymphoblastic-leukemia monthly 0.9 2023-10-25T09:13:00.000Z https://lymphoblastic-hub.com/medical-information/is-car-t-cell-therapy-a-safe-and-effective-treatment-option-for-rr-t-all-and-lymphoma monthly 0.9 2023-11-24T12:50:00.000Z https://lymphoblastic-hub.com/medical-information/efficacy-and-safety-of-cd22cd19-dual-targeted-car-t-cell-therapy-in-b-cell-malignancies monthly 0.9 2023-11-01T12:06:00.000Z https://lymphoblastic-hub.com/medical-information/when-and-how-should-mrd-be-measured-in-philadelphia-negative-all monthly 0.9 2023-10-24T12:03:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-challenges-of-sequencing-immunotherapies-in-adults-with-all monthly 0.9 2023-10-17T12:47:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-toxicity-in-brazil-and-guatemala monthly 0.9 2023-10-10T14:20:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-treatment-challenges-in-brazil-and-guatemala monthly 0.9 2023-10-10T14:11:00.000Z https://lymphoblastic-hub.com/medical-information/the-role-of-the-gut-microbiota-in-car-t-cell-therapy-outcomes monthly 0.9 2023-10-13T11:02:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-diagnostic-challenges-in-brazil-and-guatemala monthly 0.9 2023-10-10T14:02:00.000Z https://lymphoblastic-hub.com/medical-information/progress-of-targeted-therapies-and-immunotherapies-in-t-alllbl monthly 0.9 2023-10-03T09:43:00.000Z https://lymphoblastic-hub.com/medical-information/prognostic-impact-of-ngs-mrd-and-its-correlation-with-rt-pcr-for-bcr-abl1-in-ph-positive-all monthly 0.9 2023-09-27T11:17:00.000Z https://lymphoblastic-hub.com/medical-information/european-commission-approved-jzp458-for-the-treatment-of-all-and-lymphoblastic-lymphoma monthly 0.9 2026-02-20T16:04:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-toxicity monthly 0.9 2023-10-10T13:58:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-treatment-challenges monthly 0.9 2023-09-07T15:59:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-all-diagnostic-challenges monthly 0.9 2023-09-07T15:56:00.000Z https://lymphoblastic-hub.com/medical-information/real-world-efficacy-of-car-t-cells-for-posttransplant-relapse-in-patients-with-b-all monthly 0.9 2023-08-18T11:54:00.000Z https://lymphoblastic-hub.com/medical-information/ecog-acrin-e1910-subgroup-analysis-impact-of-age-and-mrd-on-blinatumomab-outcomes-in-newly-diagnosed-ph-b-all monthly 0.9 2023-08-24T14:55:00.000Z https://lymphoblastic-hub.com/medical-information/is-mini-hyper-cvd-plus-venetoclax-safe-and-effective-in-patients-with-rr-ph-all monthly 0.9 2023-08-18T11:23:00.000Z https://lymphoblastic-hub.com/medical-information/results-from-the-phase-iii-aall1331-trial-blinatumomab-in-low-risk-children-and-aya-patients-with-b-all-in-first-relapse monthly 0.9 2023-08-14T13:33:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-vs-imatinib-as-a-frontline-treatment-for-patients-with-ph-all monthly 0.9 2023-08-07T14:29:00.000Z https://lymphoblastic-hub.com/medical-information/mini-hyper-cvd-plus-inotuzumab-ozogamicin-blinatumomab-in-adult-rr-ph-b-all monthly 0.9 2023-08-02T10:48:00.000Z https://lymphoblastic-hub.com/medical-information/novel-treatment-in-philadelphia-negative-all-key-updates-from-eha-2023 monthly 0.9 2023-12-05T13:40:00.000Z https://lymphoblastic-hub.com/medical-information/novel-treatment-approaches-in-ph-all-key-updates-from-eha-2023 monthly 0.9 2023-07-27T11:59:00.000Z https://lymphoblastic-hub.com/medical-information/cns-leukemia-in-pediatric-all-mechanisms-diagnostics-and-treatment monthly 0.9 2023-07-28T11:13:00.000Z https://lymphoblastic-hub.com/medical-information/efficacy-and-safety-of-obe-cel-in-rr-adult-b-all-phase-ii-felix-study monthly 0.9 2023-07-12T13:54:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-versus-imatinib-in-combination-with-low-intensity-chemotherapy-in-patients-with-newly-diagnosed-ph-all-phallcon-trial monthly 0.9 2023-07-12T13:33:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-in-infant-with-kmt2a-rearranged-all monthly 0.9 2023-07-14T13:29:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-and-blinatumomab-in-older-adults-with-newly-diagnosed-b-all-alliance-trial monthly 0.9 2023-09-06T12:05:00.000Z https://lymphoblastic-hub.com/medical-information/first-in-human-trial-of-revumenib-in-patients-with-kmt2a-rearranged-or-npm1-mutated-leukemia monthly 0.9 2023-06-20T09:59:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-combined-with-dasatinib-and-steroids-in-older-patients-with-philadelphia-positive-all-results-from-a-phase-ii-study monthly 0.9 2023-06-29T10:09:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-receives-fda-approval-for-mrd-philadelphia-negative-b-all monthly 0.9 2024-07-25T08:33:00.000Z https://lymphoblastic-hub.com/medical-information/donorderived-cd7-car-tcell-therapy-in-rr-tall-results-from-a-phase-i-study monthly 0.9 2023-06-13T13:24:00.000Z https://lymphoblastic-hub.com/medical-information/late-effects-of-disease-and-treatment-in-survivors-of-adult-all monthly 0.9 2023-06-07T13:37:00.000Z https://lymphoblastic-hub.com/medical-information/long-term-outcomes-following-car-t-cell-therapy-in-b-cell-malignancies monthly 0.9 2023-06-06T13:55:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2023 monthly 0.9 2023-06-08T14:10:00.000Z https://lymphoblastic-hub.com/medical-information/eha2023-abstracts-what-s-hot-in-all monthly 0.9 2023-06-06T08:23:00.000Z https://lymphoblastic-hub.com/medical-information/asco-2023 monthly 0.9 2023-05-31T10:28:00.000Z https://lymphoblastic-hub.com/medical-information/what-unusual-toxicities-are-seen-in-patients-with-all-and-what-are-the-best-strategies-to-manage-them monthly 0.9 2025-08-05T13:31:00.000Z https://lymphoblastic-hub.com/medical-information/coadministration-of-cd19-and-cd22-targeted-car-t-cells-in-children-with-rr-b-cell-all monthly 0.9 2023-05-12T09:38:00.000Z https://lymphoblastic-hub.com/medical-information/car-t-cell-therapy-associated-hlh-like-syndrome monthly 0.9 2023-05-10T10:13:00.000Z https://lymphoblastic-hub.com/medical-information/novel-targeted-and-cellular-therapies-in-adult-patients-with-rr-ph-like-all monthly 0.9 2023-05-05T12:39:00.000Z https://lymphoblastic-hub.com/medical-information/graall-2005-study-impact-of-cns-involvement-on-outcomes-in-adult-patients-with-philadelphia-chromosome-negative-all monthly 0.9 2023-05-12T14:55:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-sequencing-and-combining-immunotherapies-in-all monthly 0.9 2023-05-05T12:05:00.000Z https://lymphoblastic-hub.com/medical-information/targeted-versus-conventional-therapy-in-rr-ph-like-all monthly 0.9 2023-04-27T11:14:00.000Z https://lymphoblastic-hub.com/medical-information/the-5th-edition-of-the-world-health-organization-classification-of-haematolymphoid-tumors-key-updates-to-all-classification monthly 0.9 2023-04-25T12:23:00.000Z https://lymphoblastic-hub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-26T11:18:00.000Z https://lymphoblastic-hub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2023-04-06T09:16:00.000Z https://lymphoblastic-hub.com/medical-information/omidubicel-onlv-granted-fda-approval-for-patients-with-hematologic-malignancies-eligible-for-umbilical-cord-blood-transplantation monthly 0.9 2023-04-19T09:09:00.000Z https://lymphoblastic-hub.com/medical-information/racial-and-ethnic-disparities-in-survival-outcomes-among-childhood-and-young-adult-patients-with-all monthly 0.9 2024-07-25T08:32:00.000Z https://lymphoblastic-hub.com/medical-information/association-between-pharmacogenomics-and-treatment-response-in-childhood-all monthly 0.9 2023-03-28T12:12:00.000Z https://lymphoblastic-hub.com/medical-information/management-of-cns-disease-in-adults-with-all monthly 0.9 2023-04-17T09:23:00.000Z https://lymphoblastic-hub.com/medical-information/mrd-status-as-a-predictor-of-survival-outcomes-in-patients-with-all-undergoing-allo-hsct-in-cr2-or-later monthly 0.9 2023-03-13T10:54:00.000Z https://lymphoblastic-hub.com/medical-information/orca-t-in-patients-undergoing-allo-hsct-for-hematologic-malignancies monthly 0.9 2025-04-29T15:50:00.000Z https://lymphoblastic-hub.com/medical-information/nelarabine-injection-receives-u-s-fda-approval-for-the-treatment-of-t-all-and-t-lbl monthly 0.9 2024-07-25T08:34:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-treatment-landscape-of-t-all monthly 0.9 2023-02-22T11:41:00.000Z https://lymphoblastic-hub.com/medical-information/inhibition-of-the-menin-kmt2a-interaction-in-amlall-the-augment-101-and-komet-001-trials monthly 0.9 2026-02-20T16:05:00.000Z https://lymphoblastic-hub.com/medical-information/philadelphia-negative-all-a-summary-of-hot-topics-presented-at-ash-2022 monthly 0.9 2023-02-02T09:42:00.000Z https://lymphoblastic-hub.com/medical-information/car-t-2023 monthly 0.9 2023-02-07T14:12:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-geographical-barriers-to-accessing-specialty-cancer-care-among-adolescents-and-young-adults-with-all monthly 0.9 2023-02-01T10:31:00.000Z https://lymphoblastic-hub.com/medical-information/novel-treatment-approaches-in-ph-all-key-updates-from-ash-2022 monthly 0.9 2023-02-01T10:21:00.000Z https://lymphoblastic-hub.com/medical-information/how-to-provide-better-supportive-care-to-patients-with-acute-lymphoblastic-leukemia monthly 0.9 2023-01-26T15:24:00.000Z https://lymphoblastic-hub.com/medical-information/how-to-treat-relapse-in-acute-lymphoblastic-leukemia-without-car-t-cell-therapy monthly 0.9 2023-01-26T15:18:00.000Z https://lymphoblastic-hub.com/medical-information/global-socioeconomic-disparities-in-patients-with-all-key-updates-from-ash-2022 monthly 0.9 2023-01-20T11:10:00.000Z https://lymphoblastic-hub.com/medical-information/does-consolidation-therapy-with-blinatumomab-improve-survival-in-newly-diagnosed-adult-with-b-all-in-mrd-remission monthly 0.9 2023-08-08T12:53:00.000Z https://lymphoblastic-hub.com/medical-information/phase-ii-trial-results-of-inotuzumab-ozogamicin-in-older-patients-with-de-novo-b-all-gmall-initial1-trial monthly 0.9 2023-01-18T13:24:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-diagnostic-approaches-and-risk-stratification-in-t-all monthly 0.9 2023-01-09T15:16:00.000Z https://lymphoblastic-hub.com/medical-information/does-adding-inotuzumab-ozogamicin-to-frontline-therapy-improve-survival-outcomes-for-adults-with-b-all monthly 0.9 2023-02-01T11:08:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-in-newly-diagnosed-adult-patients-with-all-in-mrd-negative-remission-results-from-econ-acrin-e1910 monthly 0.9 2026-02-23T08:55:00.000Z https://lymphoblastic-hub.com/medical-information/how-can-you-increase-asparaginase-adherence-and-manage-hypersensitivity-in-adults-with-all monthly 0.9 2023-01-26T09:40:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-plus-ponatinib-in-adult-patients-with-philadelphia-positive-all-results-from-a-phase-ii-study monthly 0.9 2022-12-22T11:30:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-genetic-heterogeneity-incidence-and-prognosis-of-t-all monthly 0.9 2022-12-16T14:30:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2022 monthly 0.9 2022-12-07T11:18:00.000Z https://lymphoblastic-hub.com/medical-information/breakthrough-therapy-designation-granted-to-revumenib-by-the-fda monthly 0.9 2022-12-07T14:15:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-early-peg-asparaginase-discontinuation-in-young-adults-with-all monthly 0.9 2022-12-06T09:47:00.000Z https://lymphoblastic-hub.com/medical-information/cns-involvement-at-diagnosis-and-its-association-with-cns-toxicities-in-childhood-all monthly 0.9 2023-04-13T09:08:00.000Z https://lymphoblastic-hub.com/medical-information/ash-2022-abstracts-what-s-hot-in-acute-lymphoblastic-leukemia monthly 0.9 2023-02-09T11:59:00.000Z https://lymphoblastic-hub.com/medical-information/patient-and-physician-perceptions-of-palliative-care-during-transplant monthly 0.9 2022-11-07T14:13:00.000Z https://lymphoblastic-hub.com/medical-information/socioeconomic-challenges-in-diagnosis-and-treatment-of-patients-with-all monthly 0.9 2022-11-02T15:39:00.000Z https://lymphoblastic-hub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-11-21T11:17:00.000Z https://lymphoblastic-hub.com/medical-information/tisagenlecleucel-therapy-in-infants-and-children-3-years-of-age-with-relapsedrefractory-b-cell-all monthly 0.9 2022-10-21T13:18:00.000Z https://lymphoblastic-hub.com/medical-information/article-title-required-character-limit-75-90-excluding-spaces-ponatinib-chemotherapy-and-transplant-in-adults-with-ph-all-results-from-the-phase-ii-ponafinil-trial monthly 0.9 2024-07-23T13:40:00.000Z https://lymphoblastic-hub.com/medical-information/rehabilitation-strategies-for-patients-undergoing-car-t-cell-therapy monthly 0.9 2022-09-27T15:08:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-epidemiology-and-treatment-landscape-of-ph-positive-all monthly 0.9 2023-04-21T11:14:00.000Z https://lymphoblastic-hub.com/medical-information/phase-ii-study-of-blinatumomab-in-patients-with-b-all-and-positive-mrd-at-a-minimum-threshold-of-104 monthly 0.9 2022-09-15T10:46:00.000Z https://lymphoblastic-hub.com/medical-information/european-commission-grants-european-marketing-authorization-to-brexucabtagene-autoleucel-for-the-treatment-of-patients-with-rr-b-all monthly 0.9 2022-09-16T14:42:00.000Z https://lymphoblastic-hub.com/medical-information/treatment-of-ph-like-all monthly 0.9 2022-11-14T09:45:00.000Z https://lymphoblastic-hub.com/medical-information/clinical-practice-guidelines-on-infectious-complications-of-targeted-drugs-and-biotherapies-european-conference-on-infections-in-leukaemia-ecil monthly 0.9 2026-01-16T19:23:00.000Z https://lymphoblastic-hub.com/medical-information/asparaginase-re-exposure-after-cerebral-sinovenous-thrombosis-in-patients-aged-1-45-years-with-all monthly 0.9 2022-08-04T13:49:00.000Z https://lymphoblastic-hub.com/medical-information/combination-therapy-in-patients-with-philadelphia-chromosome-negative-b-all monthly 0.9 2022-07-27T15:01:00.000Z https://lymphoblastic-hub.com/medical-information/which-tests-are-needed-for-risk-stratification-in-all monthly 0.9 2022-08-11T14:43:00.000Z https://lymphoblastic-hub.com/medical-information/how-i-sequence-treatment-for-rr-b-all monthly 0.9 2023-09-14T07:50:00.000Z https://lymphoblastic-hub.com/medical-information/article-title-required-character-limit-75-90-excluding-spaces-brexucabtagene-autoleucel-receives-a-positive-opinion-from-ema-chmp-for-the-treatment-of-patients-with-rr-b-all monthly 0.9 2022-07-26T13:24:00.000Z https://lymphoblastic-hub.com/medical-information/zuma-3-trial-update-of-brexucabtagene-autoleucel-in-adult-patients-with-rr-b-all monthly 0.9 2022-09-16T14:43:00.000Z https://lymphoblastic-hub.com/medical-information/visual-abstract-blinatumomab-added-to-prephase-and-consolidation-phase-in-newly-diagnosed-patients-with-all-hovon146all monthly 0.9 2024-07-11T21:06:00.000Z https://lymphoblastic-hub.com/medical-information/fda-granted-fast-track-and-rare-pediatric-disease-designations-to-wu-cart-007-for-rr-t-alllbl monthly 0.9 2022-07-22T11:28:00.000Z https://lymphoblastic-hub.com/medical-information/article-title-required-character-limit-75-90-excluding-spaces-five-year-follow-up-of-tisagenlecleucel-in-pediatric-and-young-adult-patients-with-rr-b-all-eliana-trial monthly 0.9 2022-12-08T16:03:00.000Z https://lymphoblastic-hub.com/medical-information/aall1931-erwinia-asparaginase-in-all monthly 0.9 2022-07-14T14:09:00.000Z https://lymphoblastic-hub.com/medical-information/does-adding-blinatumomab-to-frontline-therapy-improve-survival-outcomes-for-adults-with-b-all monthly 0.9 2022-11-14T10:24:00.000Z https://lymphoblastic-hub.com/medical-information/daratumumab-for-relapsedrefractory-t-cell-all-or-ll-results-from-delphinus-study monthly 0.9 2022-07-13T08:15:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-the-cellular-origin-of-all monthly 0.9 2022-07-05T08:24:00.000Z https://lymphoblastic-hub.com/medical-information/are-chemotherapy-free-treatment-strategies-an-option-for-patients-with-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/two-year-follow-up-of-kte-x19-in-adult-patients-with-rr-b-all-zuma-3-trial monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-overcomes-the-poor-prognostic-impact-of-measurable-residual-disease-in-pediatric-high-risk-first-relapse-b-cell-precursor-acute-lymphoblastic-leukemia monthly 0.9 2022-06-21T09:08:00.000Z https://lymphoblastic-hub.com/medical-information/visual-abstract-inotuzumab-ozogamicin-as-single-agent-in-pediatric-patients-with-relapsed-and-refractory-acute-lymphoblastic-leukemia monthly 0.9 2022-11-04T15:21:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2022 monthly 0.9 2022-07-29T14:55:00.000Z https://lymphoblastic-hub.com/medical-information/eha-2022-abstracts-what-s-hot-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/asco-2022 monthly 0.9 2022-09-02T10:11:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-diagnosis-of-ph-like-all monthly 0.9 2022-11-14T09:46:00.000Z https://lymphoblastic-hub.com/medical-information/tisagenlecleucel-in-pediatric-and-young-adult-patients-with-down-syndrome-associated-relapsedrefractory-acute-lymphoblastic-leukemia monthly 0.9 2022-05-16T16:22:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-the-genomic-landscape-biology-epidemiology-and-prognosis-of-ph-like-all monthly 0.9 2022-11-14T12:48:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-injection-approved-in-china-for-pediatric-relapsed-or-refractory-cd19-b-cell-precursor-acute-lymphoblastic-leukemia monthly 0.9 2024-07-25T08:34:00.000Z https://lymphoblastic-hub.com/medical-information/children-s-oncology-group-trial-aall1231-a-phase-iii-clinical-trial-of-bortezomib-in-newly-diagnosed-t-cell-acute-lymphoblastic-leukemia-and-lymphoma monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/frontline-ponatinib-with-steroids-for-patients-with-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/challenges-and-future-directions-for-access-to-cell-therapies-a-global-perspective monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/sequential-treatment-with-blinatumomab-and-inotuzumab-in-patients-with-relapsed-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/eryaspase-for-all-results-from-the-nor-graspall-2016-study monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-does-gvhd-affect-outcomes-for-pediatric-patients-undergoing-allo-sct-for-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/risk-factors-for-induction-related-mortality-in-aya-and-adult-patients-with-all-in-resource-constrained-settings monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-the-role-of-sequencing-for-mrd-assessment-and-predicting-relapse-for-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/wu-cart-007-receives-orphan-drug-designation-for-t-all monthly 0.9 2025-02-12T18:12:00.000Z https://lymphoblastic-hub.com/medical-information/management-of-short-medium-and-long-term-complications-in-patients-receiving-car-t-cell-therapy monthly 0.9 2022-03-17T16:00:00.000Z https://lymphoblastic-hub.com/medical-information/how-effective-is-targeted-therapy-for-ph-like-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-common-are-cardiotoxic-events-in-patients-receiving-cd19-car-t-cells-what-are-the-risk-factors monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-for-b-all-rialto-final-analysis monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/real-world-outcomes-with-tisagenlecleucel-in-cayas-with-rr-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-do-car-t-cell-recipients-respond-to-covid-19-vaccination monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-supportive-care-is-needed-for-patients-receiving-car-t-cell-therapy monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-the-role-of-wgs-and-wts-for-the-genetic-classification-of-adult-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/nelarabine-plus-standard-chemotherapy-does-not-improve-survival-in-adult-patients-with-t-all-first-analysis-of-ukall-14-study monthly 0.9 2022-01-25T15:08:00.000Z https://lymphoblastic-hub.com/medical-information/progress-in-car-t-therapy-for-t-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/frontline-treatments-for-older-patients-with-ph-b-all monthly 0.9 2026-02-02T17:37:00.000Z https://lymphoblastic-hub.com/medical-information/why-are-novel-tkis-needed-for-ph-all-what-does-this-mean-for-patients monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/aall1331-blinatumomab-improves-outcomes-for-some-low-risk-pediatric-and-aya-patients-with-first-relapse-of-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-prognostic-impact-of-chromosomal-abnormalities-and-copy-number-alterations-in-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-addition-of-blinatumomab-to-the-interfant-06-study-protocol-for-infants-with-newly-diagnosed-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-are-advances-in-all-genomics-informing-new-treatment-approaches monthly 0.9 2022-01-13T09:10:00.000Z https://lymphoblastic-hub.com/medical-information/hla-mis-matching-in-haploidentical-transplantation monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/comparison-of-outcomes-in-adolescent-and-young-adult-patients-versus-younger-patients-with-high-risk-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/ash2021-abstracts-what-s-hot-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/educational-theme-or-aya-and-adult-b-all-two-novel-high-risk-subtypes-expressing-cdx2-and-idh-12-mutations monthly 0.9 2022-11-14T09:47:00.000Z https://lymphoblastic-hub.com/medical-information/which-factors-influence-the-need-for-allo-sct-consolidation-in-patients-treated-with-car-t-cells monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/a-review-of-antibody-and-cellular-immunotherapies-for-adults-with-relapsedrefractory-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/haploidentical-hematopoietic-cell-transplantation-a-preferred-approach-for-adult-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/amelia-a-phase-1-trial-of-car-t-cells-with-dual-cd19-and-cd22-targeting-in-pediatric-and-young-adult-patients-with-rr-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/car-t-cell-therapy-for-cns-rr-all-a-post-hoc-analysis-of-pooled-data-from-five-clinical-trials monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/humoral-and-cellular-responses-to-tisagenlecleucel monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/mrd-and-survival-outcomes-in-patients-with-down-syndrome-and-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs monthly 0.9 2024-07-25T08:30:00.000Z https://lymphoblastic-hub.com/medical-information/educational-themeclinical-significance-of-genetic-alterations-in-patients-with-b-all monthly 0.9 2022-11-14T12:49:00.000Z https://lymphoblastic-hub.com/medical-information/the-impact-of-kmt2a-rearrangements-and-allo-hsct-on-survival-outcomes-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/droplet-digital-pcr-vs-rt-pcr-for-mrd-monitoring-in-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/brexucabtagene-autoleucel-approved-by-the-fda-for-use-in-adult-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/omission-of-vincristinedexamethasone-pulse-therapy-does-not-adversely-affect-outcome-in-low-risk-pediatric-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/fda-approval-of-ruxolitinib-for-the-treatment-of-patients-with-chronic-gvhd monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-are-transplant-options-evolving-for-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-does-mrd-guide-therapeutic-decisions-in-all monthly 0.9 2021-09-24T15:38:00.000Z https://lymphoblastic-hub.com/medical-information/when-should-a-hyper-cvad-regimen-be-considered-for-all-and-when-not monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/does-current-reporting-on-car-t-cell-therapy-in-clinical-trials-overestimate-efficacy-why-the-distinction-between-itt-and-mitt-populations-is-important monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/could-ponatinib-blinatumomab-substitute-chemo-allo-hsct-as-frontline-therapy-for-ph-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/using-whole-transcriptome-sequencing-for-the-genetic-stratification-of-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/a-predictive-prognostic-scoring-system-based-on-residual-disease-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/prediction-of-non-adherence-to-oral-mercaptopurine-in-pediatric-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/phase-i-zuma-4-trial-long-term-follow-up-of-brexu-cel-in-pediatricadolescent-rr-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/consensus-definitions-for-response-criteria-in-pediatric-all-results-from-the-ponte-di-legno-consortium monthly 0.9 2026-01-16T19:24:00.000Z https://lymphoblastic-hub.com/medical-information/prognostic-significance-of-novel-all-subtypes-adding-to-the-framework-of-mrd-directed-therapy monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/kte-x19-autologous-anti-cd19-car-t-cell-therapy-in-patients-with-rr-b-all-long-term-phase-i-zuma-4-results monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/when-is-it-safe-to-schedule-an-allo-hsct-after-covid-19-infection monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-caloric-restriction-and-exercise-on-chemotherapy-efficacy-in-young-adult-patients-with-b-all-the-ideal-trial monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/title-the-ukall-heh-model-could-potentially-redefine-low-risk-high-hyperdiploidy-in-pediatric-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/pre-emptive-versus-prophylactic-use-of-tkis-after-allo-sct-in-patients-with-philadelphia-chromosome-positive-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/d-alba-trial-how-can-we-improve-dasatinib-results-in-newly-diagnosed-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/updated-results-from-the-d-alba-trial-of-dasatinib-plus-blinatumomab-in-newly-diagnosed-adult-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-main-advances-in-patient-care-we-are-seeing-with-novel-agents-for-leukemia monthly 0.9 2022-09-02T10:11:00.000Z https://lymphoblastic-hub.com/medical-information/germline-predisposition-mutations-and-recurrent-somatic-mutations-in-korean-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-spleen-as-a-site-for-residual-disease-in-t-cell-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/could-ponatinib-blinatumomab-substitute-chemo-allo-hsct-as-frontline-therapy-for-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-main-advances-in-patient-care-that-we-are-seeing-with-novel-agents-for-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-role-of-regnase-1-in-car-t-cell-therapy-a-potential-target-to-improve-responses-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/is-the-anti-cd19-car-t-brexu-cel-safe-and-effective-in-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/eha2021-abstracts-what-s-hot-in-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-has-targeted-therapy-impacted-the-prognosis-for-patients-with-a-high-disease-burden-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/runx2-as-a-dependency-factor-and-critical-mediator-of-disease-progression-in-high-risk-t-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/long-term-data-with-cd19-car-t-cell-therapy-in-children-and-young-adults-with-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/why-should-car-t-cell-therapy-be-used-earlier-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/inotuzumab-ozogamicin-effective-for-the-treatment-of-newly-diagnosed-older-patients-and-pediatric-patients-with-rr-bcp-all-results-from-two-studies monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-as-first-salvage-versus-second-or-later-salvage-in-adults-with-relapsedrefractory-b-cell-precursor-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/investigational-new-drug-status-and-fast-track-designation-granted-by-fda-to-smart-101-a-progenitor-t-cell-product-for-aml-and-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-major-challenges-for-car-t-cell-therapies-in-europe-during-the-covid-19-pandemic monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/a-role-for-macrophages-in-remodeling-the-bone-marrow-microenvironment-in-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/results-from-the-cog-aall0331-trial-in-a-low-risk-subset-of-children-with-standard-risk-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/fda-clears-investigational-new-drug-application-for-cd19-directed-car-nk-therapy-nkx019 monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-recent-advances-in-immunotherapy-for-adult-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-is-relapsedrefractory-all-currently-managed-in-korea-kr monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/survival-and-prognostic-factors-of-aya-patients-with-all-receiving-a-modified-pediatric-bfm-90-regimen monthly 0.9 2026-03-25T09:15:00.000Z https://lymphoblastic-hub.com/medical-information/impact-of-vitamins-k2-and-d3-on-bone-mineral-density-in-pediatric-patients-with-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/sndx-5613-shows-encouraging-overall-response-rate-in-relapsedrefractory-acute-leukemias monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/germline-mutations-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/too-much-of-a-good-thing-an-in-vitro-study-with-dual-srcabl-kinase-inhibitor-and-blinatumomab-suggests-some-combination-treatments-for-ph-all-may-not-work-well-together monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/antibiotic-treatment-is-associated-with-decreased-response-to-car-t-cell-therapy monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/progress-in-immunotherapy-for-hematologic-malignancies monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/have-you-seen-an-improvement-in-os-for-patients-who-relapse-after-hsct-over-the-past-20-years monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/mixed-phenotype-acute-leukemia-a-review-of-diagnostic-and-treatment-approaches monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/supplemental-biologics-license-application-submitted-for-brexucabtagene-autoleucel-for-use-in-rr-b-cell-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/advances-of-cell-therapies-in-china-reducing-manufacturing-time-with-fast-dual-car-t-cells monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-new-in-car-t-cell-therapy-for-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/when-would-you-favor-haploidentical-hsct-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/development-of-childhood-b-all-triggering-factors-and-prospective-treatments monthly 0.9 2024-07-25T08:32:00.000Z https://lymphoblastic-hub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2026-01-16T19:25:00.000Z https://lymphoblastic-hub.com/medical-information/comparison-of-toxicities-in-young-adults-with-all-in-calgb-10403-and-cog-aall0232 monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/novel-concepts-to-target-cd22-with-car-t-cell-therapy-for-rr-b-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/hyper-cvad-with-sequential-blinatumomab-for-the-treatment-of-adult-patients-with-newly-diagnosed-philadelphia-chromosome-negative-b-cell-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/genetic-markers-in-the-prognosis-of-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-new-for-car-t-cell-therapy-for-adult-patients-with-all monthly 0.9 2021-03-19T10:15:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-prior-to-cd19-car-t-cell-therapy-for-the-treatment-of-relapserefractory-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/when-should-we-consider-allo-hsct-in-a-patient-with-all-and-when-not monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-do-constitutively-active-signaling-pathways-impact-response-to-treatment-in-pediatric-t-all monthly 0.9 2021-03-19T09:53:00.000Z https://lymphoblastic-hub.com/medical-information/interfant-06-study-why-should-we-assess-end-of-consolidation-mrd-in-infants-with-all monthly 0.9 2021-03-19T09:53:00.000Z https://lymphoblastic-hub.com/medical-information/promising-results-for-treating-patients-with-aggressive-lymphoblastic-leukemia-using-genome-edited-allogeneic-car-t-cells monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/phase-i-results-show-venetoclax-and-navitoclax-combination-is-tolerable-and-associated-with-responses-in-pediatric-patients-with-rr-all-and-ll monthly 0.9 2024-11-27T14:29:00.000Z https://lymphoblastic-hub.com/medical-information/how-can-nk-cells-act-as-reliable-predictors-and-be-translated-to-diagnostics-and-treatment-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/ponatinib-and-venetoclax-for-patients-with-philadelphia-chromosome-positive-all-interim-results-of-a-phase-iii-study monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/is-chemo-free-ponatinib-venetoclax-and-dexamethasone-safeeffective-in-patients-with-rr-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-is-superior-to-chemotherapy-consolidation-for-children-with-high-risk-b-cell-precursor-all-at-first-relapse monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/should-we-be-mindful-of-orthopedic-toxicities-in-adolescent-and-young-adult-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/asparaginase-toxicity-issues-and-potential-solutions monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/current-recommendations-for-therapy-related-toxicity-management-in-all monthly 0.9 2026-01-16T19:25:00.000Z https://lymphoblastic-hub.com/medical-information/old-and-new-adcs-for-the-treatment-of-all-and-aml monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-effect-of-inotuzumab-ozogamicin-treatment-exposure-and-cycles-on-rr-all-outcomes monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/balli-01-study-is-ucart22-an-allogeneic-anti-cd22-car-t-cell-product-safe-and-effective monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/car-t-cell-therapy-how-can-we-improve-toxicity-management monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-do-you-manage-asparaginase-toxicity-in-your-aya-patients-with-all monthly 0.9 2021-03-19T10:39:00.000Z https://lymphoblastic-hub.com/medical-information/how-should-we-best-sequence-the-new-targeted-therapies-in-relapsed-b-all monthly 0.9 2021-11-26T13:45:00.000Z https://lymphoblastic-hub.com/medical-information/how-should-we-treat-a-patient-who-has-a-molecular-relapse-after-transplant monthly 0.9 2021-03-19T09:55:00.000Z https://lymphoblastic-hub.com/medical-information/how-should-we-treat-older-patients-with-all monthly 0.9 2024-07-25T08:30:00.000Z https://lymphoblastic-hub.com/medical-information/are-mini-hyper-cvd-combinations-adequate-for-older-adults-with-all monthly 0.9 2021-03-19T09:56:00.000Z https://lymphoblastic-hub.com/medical-information/recurrent-immature-ig-gene-rearrangements-in-tp53-mutated-b-precursor-adult-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/regenerative-medicine-advanced-therapy-and-orphan-drug-designation-given-to-orca-t monthly 0.9 2025-04-29T15:50:00.000Z https://lymphoblastic-hub.com/medical-information/what-have-been-the-recent-advances-in-all-therapy monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/coagulation-fxiii-a-expression-patterns-can-predict-outcomes-in-pediatric-bcp-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-current-challenges-in-all-that-need-to-be-addressed monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/results-from-the-aall0434-phase-iii-trial-evaluating-nelarabine-in-newly-diagnosed-pediatric-and-young-adult-t-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/phase-iii-study-confirms-superior-outcomes-using-haploidentical-donors-in-patients-with-pretransplant-mrd-positive-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-s-the-latest-innovation-in-car-t-therapy-fast-off-dual-targeting-and-other-new-tricks monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/combining-ofatumumab-and-hyper-cvad-therapy-for-cd20-positive-ph-negative-b-cell-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/late-relapse-in-all-results-from-an-8-year-follow-up-of-the-mrc-ukallxiiecog-e2993-trial monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/young-adult-and-pediatric-all-current-induction-regimens-and-prognostic-factors monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/anti-cd22-car-t-cell-potency-and-toxicity-is-affected-by-cd4cd8-t-cell-selection monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/blinatumomab-induces-cures-in-adults-with-minimal-residual-disease-b-cell-precursor-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/current-treatment-landscape-of-acute-lymphoblastic-leukemia monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/anti-cd22-a-promising-new-car-t-target-for-rr-all-results-from-a-phase-i-trial monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/venetoclax-and-navitoclax-for-rr-all-and-lymphoblastic-lymphoma monthly 0.9 2024-11-27T14:30:00.000Z https://lymphoblastic-hub.com/medical-information/tki-maintenance-therapy-post-allogeneic-hct-improves-outcomes-in-patients-with-ph-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/can-ruxolitinib-be-safely-combined-with-regulatory-t-cells-to-enhance-efficacy-in-treating-cgvhd monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/comparison-of-reduced-intensity-conditioning-regimens-for-allo-hsct-in-patients-with-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-is-the-best-donor-or-graft-source-for-patients-lacking-hla-matched-donors monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/phase-iii-study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-meets-primary-endpoint monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/treosulfanfludarabinethiotepa-conditioning-treatment-before-allogeneic-hematopoietic-stem-cell-transplantation-for-children-with-hematological-malignancies monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/the-correlation-between-cd34-cell-dose-and-dfs-in-matched-related-donor-pbsc-allo-sct monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/ebmt-and-jacie-recommendations-for-the-management-of-car-t-cell-therapy monthly 0.9 2026-01-16T19:26:00.000Z https://lymphoblastic-hub.com/medical-information/hla-dpb1-mismatch-models-after-unrelated-donor-stem-cell-transplantation monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/effect-of-conditioning-regimen-intensity-after-haploidentical-transplantation monthly 0.9 2020-11-12T02:56:00.000Z https://lymphoblastic-hub.com/medical-information/is-tki-therapy-effective-in-patients-with-abl-class-fusion-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/is-auto1-car-t-cell-therapy-effective-in-reducing-toxicity-and-enhancing-t-cell-activation-in-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/how-should-personalized-treatment-of-all-be-approached monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/medical-information/what-are-the-new-subtypes-in-pediatric-all monthly 0.9 2022-07-04T10:22:00.000Z https://lymphoblastic-hub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:27:00.000Z https://lymphoblastic-hub.com/about-us/helen-croxall monthly 0.6 2026-03-10T10:27:00.000Z https://lymphoblastic-hub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:27:00.000Z https://lymphoblastic-hub.com/about-us/a-campbell-warner monthly 0.6 2026-03-10T10:27:00.000Z https://lymphoblastic-hub.com/about-us/jennifer-higgins monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/haimanti-mandal monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/devon-else monthly 0.6 2026-03-10T10:25:00.000Z https://lymphoblastic-hub.com/about-us/nathan-fisher monthly 0.6 2026-02-25T14:50:00.000Z https://lymphoblastic-hub.com/about-us/amy-hopkins monthly 0.6 2026-02-25T14:50:00.000Z https://lymphoblastic-hub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:08:00.000Z https://lymphoblastic-hub.com/about-us/natasha-fort monthly 0.6 2026-02-25T14:50:00.000Z https://lymphoblastic-hub.com/about-us/addy-dullaghan monthly 0.6 2026-02-25T14:50:00.000Z https://lymphoblastic-hub.com/about-us/alison-roddam monthly 0.6 2026-02-25T14:50:00.000Z https://lymphoblastic-hub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:41:00.000Z https://lymphoblastic-hub.com/about-us/abbie-mckillop monthly 0.6 2026-04-02T14:41:00.000Z https://lymphoblastic-hub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:41:00.000Z https://lymphoblastic-hub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:41:00.000Z https://lymphoblastic-hub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:41:00.000Z https://lymphoblastic-hub.com/contributors/charles-mullighan monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/franco-locatelli monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/wendy-stock monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/oliver-ottmann monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/sabina-chiaretti monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/andrea-biondi monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/mark-litzow monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/nicola-gokbuget monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/anita-rijneveld monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/andre-baruchel monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/kjeld-schmiegelow monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/jose-maria-ribera monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/nicolas-boissel monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/elias-jabbour monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/daniel-deangelo monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/vikram-mathews monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/ibrahim-t-aldoss-1 monthly 0.6 2025-04-22T15:33:00.000Z https://lymphoblastic-hub.com/contributors/luke-maese monthly 0.6 2026-02-16T09:09:00.000Z https://lymphoblastic-hub.com/steering-committees monthly 0.7 2026-04-03T18:57:38.688Z https://lymphoblastic-hub.com/about-us monthly 0.7 2026-04-03T18:57:38.688Z https://lymphoblastic-hub.com/newsletter monthly 0.7 2026-04-03T18:57:38.688Z https://lymphoblastic-hub.com/our-hubs monthly 0.7 2026-04-03T18:57:38.688Z https://lymphoblastic-hub.com/contact monthly 0.7 2026-04-03T18:57:38.688Z